Products
Online InquiryAccelerate Your Glycan-Based Discoveries!
Creative Biolabs overcomes these challenges through customized glycan-specific antibody constructs, integrating advanced glycoengineering systems and computational glycosylation design tools to produce structurally defined glycoprotein probes that accelerate therapeutic target validation and immune modulator development.
Contact our team to get an inquiry now!
Anti-Glycan Antibody
Carbohydrate-targeting antibodies represent critical reagents for foundational biomedical research. Owing to the technical limitations in resolving native glycan structures within complex biological systems, antibody mediated detection remains the predominant approach for carbohydrate epitope analysis. This analytical paradigm integrates three core methodologies: spatial glycan profiling through immunostaining, immunoblot-based molecular characterization, and a quantitative immunoassay platform. Operationally, these immunoglobulins serve dual capacities: as signaling mediators (activating/inhibiting glycan-mediated pathways) and affinity-based isolation tools for glycosylated proteins. Significantly, they enable detection of pathological glycoconjugates, evidenced by MBr1's critical function in establishing Globo H as a tumor-selective glycoantigen. Application validity necessitates calibrated immunoglobulin lots with validated binding profiles.
Antibodies targeting carbohydrate antigens demonstrate substantial translational utility across medical domains. The disialoganglioside GD2-specific immunoglobulins now constitute integral components of first-line immunotherapy regimens for high-risk neuroblastoma management. Numerous carbohydrate-directed antibody candidates—including those recognizing GD3 gangliosides, GM2 glycolipids, fucosylated GM1 variants, and Lewis Y epitopes—are undergoing rigorous evaluation in oncology clinical trials. Beyond therapeutic applications, these biomolecules serve critical diagnostic functions; sLeA-targeting immunoglobulins, for instance, enable precise cancer biomarker quantification and disease progression surveillance through glycan microarray platforms.
Distributed under Freepik License, from Freepik.
Anti-glycan antibodies play pivotal roles in biomedical research and clinical practice. Therapeutic mAbs directed against tumor or pathogen associated glycans have entered clinical trials. These biomolecules also support diagnostic evaluation, disease progression tracking, and functional glycan studies. High-specificity anti-glycan mAbs remain limited, highlighting the demand for innovative discovery platforms.
Click the bottom to discover our products.
Leveraging advanced antibody engineering systems, Creative Biolabs delivers diverse off-the-shelf and tailored recombinant glycan-targeting immunoglobulins (monoclonal and polyclonal variants) for scientific investigations and assay development. Complementing these offerings, our comprehensive glycobiology-focused antibody development solutions enable researchers to generate antibodies specific to desired carbohydrate epitopes for diagnostic biomarker detection and therapeutic intervention strategies.
Published Data
Fig.2 Cross-reactivity of IgG in various filarial infection and control plasmas to B. malayi N-linked and GSL glycan motifs.1
This investigation examined IgG binding selectivity toward Brugia malayi glycans by probing carbohydrate microarrays with plasma from uninfected controls versus Loa loa, Onchocerca volvulus, Mansonella perstans, and Wuchereria bancrofti-infected subjects. The experiment revealed that IgG antibodies to a restricted subset of cross reactive glycans were present in the plasma of individuals infected with all four filarial species, suggesting shared antigenic structures. Moreover, sera from Onchocerca volvulus and Mansonella perstans seropositive subjects exhibited IgG reactivity against substantially broader glycoepitope panels, yielding composite seropositivity profiles matching the repertoire breadth observed in Brugia malayi infected individuals. Comprehensive profiling of IgG subclass responses targeting Brugia malayi glycans across B. malayi, Onchocerca volvulus, and Mansonella perstans infections revealed IgG1 and IgG2 as dominant mediators of glycan-directed immune reactions. A clinically significant observation emerged from the substantial decrease in IgG2 reactivity against helminth glycans in B. malayi infected patients post antiparasitic therapy. This treatment associated IgG2 diminution demonstrates diagnostic utility for tracking therapeutic outcomes and enabling pathogen specific assay development, thereby advancing understanding of nematode glycosylation patterns and host glycan targeting antibody dynamics.
What We Can Offer?
Creative Biolabs offers a comprehensive suite of products and services designed to meet your specific anti-glycan antibody needs, from initial concept to validated product.
- Monoclonal / Polyclonal Anti-Glycan Antibody Production
- Custom Synthetic Glycan Antigen Synthesis
- Antibody Characterization and Validation
- Glycan Microarray Services
- Application-Specific Antibody Optimization
Experience the Creative Biolabs Advantage - Get a Quote Today
Why Choose Us?
Creative Biolabs' glycan-targeting immunoglobulin constructs are engineered against rigorously purified glycan epitopes with immunogenicity optimization, ensuring robust functional integrity. These biologics exhibit enhanced molecular recognition and precise epitope discrimination, critical for advancing diagnostic validation platforms and therapeutic bioprocessing pipelines.
Key Advantages and Unique Features:
- High-Quality Glycan Antigens: We ensure carbohydrate antigens possess high purity and immunogenicity, foundational for generating effective anti-glycan antibodies.
- Superior Antibody Performance: Our anti-glycan antibody products are characterized by high affinity and specificity, crucial attributes for reliable research and development outcomes.
- Rigorous Quality Control: Every antibody and conjugate undergoes stringent quality control, including high-resolution mass spectrometry and nuclear magnetic resonance for synthetic glycans, and comprehensive functional assays for antibodies. This commitment to quality ensures batch-to-batch consistency and reliable performance.
- Versatile Antibody Formats & Technologies: We offer a wide range of antibody formats, including monoclonal and polyclonal antibodies. Our capabilities extend to generating various types of antibodies, such as humanized, chimeric, and bispecific formats. We leverage cutting-edge technologies like hybridoma, phage display, and DNA recombination, available based on your specific demands, to ensure an optimal development strategy for your anti-glycan antibodies.
FAQs
Here are some common questions about Creative Biolabs' Anti-Glycan Antibody Products and Services:
Q: What sets Creative Biolabs' anti-glycan antibody solutions apart from conventional approaches?
A: Our differentiating strength stems from computationally designed glycoepitopes and multivalent presentation scaffolds, representing a paradigm shift from conventional approaches utilizing heterogeneous carbohydrate sources. This enables atomic-level precision in epitope fidelity and covalent linkage optimization, generating immunoglobulins with enhanced binding discrimination and reduced cross-reactivity. Furthermore, our methodology is engineered to trigger T-helper lymphocyte activation pathways essential for sustained immunological memory, thereby elevating operational efficacy across diagnostic and therapeutic workflows.
Q: How does Creative Biolabs ensure the development of antibodies targeting complex or rare glycan structures?
A: Our chemoproteomic platforms are precision engineered to resolve stereochemical challenges in unconventional glycan topologies. Through directed glycoform remodeling of immunodominant cores and chemoenzymatic assembly, we generate antibodies targeting cryptic carbohydrate epitopes inaccessible to conventional immunological detection.
Q: For which applications are Creative Biolabs' high-affinity anti-glycan antibodies most beneficial?
A: Our multifunctional carbohydrate-targeting immunoglobulins deliver exceptional value across diverse biomedical domains. Key implementations encompass vaccinology against refractory pathogens, high-resolution diagnostics (serological subtyping platforms and biomolecular detection), passive immunotherapeutic interventions, and oncological innovations featuring glycoantigen-specific adoptive cell transfer systems.
Related Services
To further support your research and development in glycobiology, Creative Biolabs offers a suite of related services:
Creative Biolabs offers a series of anti-glycan antibody-related services for worldwide customers. To explore these capabilities, please contact us for more information.
Reference:
- Petralia, Laudine M C et al. "Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections." Frontiers in immunology vol. 14 1102344. 6 Mar. 2023, DOI:10.3389/fimmu.2023.1102344. Distributed under Open Access license CC BY 4.0, without modification.